{"id":180581,"date":"2026-02-13T04:33:01","date_gmt":"2026-02-13T09:33:01","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180581"},"modified":"2026-02-13T04:33:01","modified_gmt":"2026-02-13T09:33:01","slug":"biocon-posts-9-operating-revenue-growth-in-q3-fy26-ebitda-margin-at-22","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/biocon-posts-9-operating-revenue-growth-in-q3-fy26-ebitda-margin-at-22\/","title":{"rendered":"Biocon posts 9% operating revenue growth in Q3 FY26; EBITDA margin at 22%"},"content":{"rendered":"\n<p><strong>Biocon Limited (BSE: 532523 \/ NSE: BIOCON)<\/strong> reported consolidated operating revenue growth of 9% year-on-year for the quarter ended December 31, 2025, supported by gains in its biosimilars and generics businesses.<\/p>\n\n\n\n<p>Operating revenue for Q3 FY26 stood at \u20b94,173 crore compared with \u20b93,821 crore in Q3 FY25. Total revenue increased 11% to \u20b94,290 crore.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Financial performance<\/strong><\/h2>\n\n\n\n<p>EBITDA rose 21% year-on-year to \u20b9951 crore, with EBITDA margin at 22% compared with 20% in the prior year period. Core EBITDA increased 21% to \u20b91,221 crore, translating to a core EBITDA margin of 29%.<\/p>\n\n\n\n<p>Profit before tax (before exceptional items) increased 64% to \u20b9226 crore. Reported net profit stood at \u20b9144 crore compared with \u20b925 crore in Q3 FY25.<\/p>\n\n\n\n<p>Net R&amp;D investment for the quarter was \u20b9249 crore, representing 8% of revenue excluding Syngene.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Segment performance<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Biosimilars (Biocon Biologics)<\/strong><\/h3>\n\n\n\n<p>Revenue from operations rose 9% year-on-year to \u20b92,497 crore. EBITDA for the segment increased 44% to \u20b9700 crore, with margin expanding to 28% from 21% a year earlier.<\/p>\n\n\n\n<p>North America performance was led by oncology and immunology products, while Europe reported stable market shares and tender-led growth.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Generics<\/strong><\/h3>\n\n\n\n<p>Generics revenue increased 24% year-on-year to \u20b9851 crore, driven by GLP-1 launches in Europe and improved performance in base formulations. Segment EBITDA stood at \u20b947 crore, with margins at 5%.<\/p>\n\n\n\n<p>The company received Voluntary Action Indicated (VAI) EIRs from the U.S. FDA for its Cranbury OSD facility and Visakhapatnam API plant.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>CRDMO (Syngene)<\/strong><\/h3>\n\n\n\n<p>CRDMO revenue declined 3% year-on-year to \u20b9917 crore. Reported EBITDA for the segment was \u20b9225 crore. Management indicated performance was impacted by challenges related to one manufacturing customer.<\/p>\n\n\n\n<p>Syngene extended its strategic collaboration with Bristol Myers Squibb through 2035 and commissioned a commercial-scale liquid-filled hard gelatin capsule facility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Corporate developments<\/strong><\/h2>\n\n\n\n<p>During the quarter, Biocon completed the integration of Biocon Biologics as a wholly owned subsidiary. The transaction valued Biocon Biologics at approximately USD 5.5 billion.<\/p>\n\n\n\n<p>In January 2026, the company raised \u20b94,150 crore through a Qualified Institutions Placement, marking its second equity issuance within eight months and cumulatively raising nearly USD 1 billion.<\/p>\n\n\n\n<p>S&amp;P upgraded Biocon Biologics\u2019 long-term issuer credit rating to BB+ with a stable outlook, while Fitch revised its outlook to positive.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Outlook<\/strong><\/h2>\n\n\n\n<p>Management commentary in the presentation highlighted focus areas including portfolio expansion across biosimilars, insulins, generics and GLP-1 peptides, sustainable growth, margin expansion and improving return on capital employed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biocon Limited (BSE: 532523 \/ NSE: BIOCON) reported consolidated operating revenue growth of 9% year-on-year for the quarter ended December 31, 2025, supported by gains in its biosimilars and generics businesses. Operating revenue for Q3 FY26 stood at \u20b94,173 crore compared with \u20b93,821 crore in Q3 FY25. Total revenue increased 11% to \u20b94,290 crore. Financial [&hellip;]<\/p>\n","protected":false},"author":2390,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747,5],"tags":[10279,16408,16410,16411,16409],"class_list":["post-180581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-healthcare-stocks","category-latest","tag-biocon","tag-biocon-earnings","tag-biocon-q3-fy26","tag-biosimilars-india","tag-nse-biocon"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":141647,"url":"https:\/\/alphastreet.com\/india\/biocon-ltd-nse-biocon-ltd-q3-fy23-results-out-total-income-rise-35-yoy\/","url_meta":{"origin":180581,"position":0},"title":"Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY","author":"Divyansh_Kasana","date":"February 14, 2023","format":false,"excerpt":"Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by Kiran Mazumdar-Shaw and is now one of the largest biopharmaceutical companies in India. Biocon is primarily engaged in the production of biosimilars, generic biologics, and research-based pharmaceuticals. It also has\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170318,"url":"https:\/\/alphastreet.com\/india\/biocon-q1-fy26-earnings-results\/","url_meta":{"origin":180581,"position":1},"title":"Biocon Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 19, 2025","format":false,"excerpt":"Biocon Limited, engaged in the manufacture of biotechnology products and research services, reported its Q1 FY26 Earnings results. Q1 FY26 Earnings Results Revenue: \u20b93,942 crore, up 14.83% year-on-year (YoY) from \u20b93,433 crore in Q1 FY25. Total Expenses: \u20b93,925 crore, up 13.67% YoY from \u20b93,453 crore. Consolidated Net Profit (PAT): \u20b989\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"BIOCON Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":131754,"url":"https:\/\/alphastreet.com\/india\/infographic-biocon-opens-this-year-with-a-stellar-performance-reporting-71-growth-in-profits\/","url_meta":{"origin":180581,"position":2},"title":"Infographic: Biocon opens this year with a stellar performance reporting 71% growth in profits","author":"Chirag Gupta","date":"July 28, 2022","format":false,"excerpt":"Biocon on Wednesday reported 71% year-on-year (YoY) jump in net profit to Rs 144 crore during Q1FY23, driven by sales of biosimilar insulin glargine in the US, despite rise in research & development expenses. The drug maker reported Rs 84 crore net profit in the corresponding period of previous year.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139023,"url":"https:\/\/alphastreet.com\/india\/shares-of-biocon-research-arm-soars-as-it-reports-23-rise-in-its-revenue\/","url_meta":{"origin":180581,"position":3},"title":"Shares of Biocon research arm soars as it reports 23% rise in its revenue","author":"Chirag Gupta","date":"January 24, 2023","format":false,"excerpt":"Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted in Q3 FY22. Revenue from operations jumped 22.5% to INR 785.90 crore in the quarter ended 31 December 2022 as compared to INR 641.40 crore recorded in Q3\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173653,"url":"https:\/\/alphastreet.com\/india\/syngene-q3-fy26-earnings-results\/","url_meta":{"origin":180581,"position":4},"title":"Syngene Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 22, 2026","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172340,"url":"https:\/\/alphastreet.com\/india\/biocon-q2-fy26-earnings-results\/","url_meta":{"origin":180581,"position":5},"title":"Biocon Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 12, 2025","format":false,"excerpt":"Biocon Ltd, a prominent biotechnology company engaged in manufacturing biotechnology products and research services, reported extraordinary financial results for Q2FY26. Financial Highlights: Revenues grew 19.67% year-on-year to \u20b94,296 crore from \u20b93,590 crore. Total expenses increased 18.42% to \u20b94,205 crore from \u20b93,551 crore. Consolidated net profit skyrocketed 392.59% to \u20b9133 crore\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2390"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180581"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180581\/revisions"}],"predecessor-version":[{"id":180582,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180581\/revisions\/180582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}